Register for our free email digests:

MabVax and Telik merge
Executive Summary
MabVax Therapeutics Inc. (antibody-based cancer treatments) and public oncology drug company Telik Inc. agreed to merge and form one cancer immunotherapy drug discovery firm that will be 85%-owned by MabVax shareholders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Reverse Acquisition
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com